Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand

BACKGROUND: Prophylactic factor replacement therapy is recommended over on-demand treatment for preserving long-term joint health in hemophilia. Extended half-life products, including efmoroctocog alfa/eftrenonacog alfa (recombinant factor VIII [FVIII]/FIX Fc fusion proteins; herein rFVIIIFc/rFIXFc)...

Descripción completa

Detalles Bibliográficos
Autores principales: Álvarez-Román, María-Teresa, Shapiro, Amy D., Ragni, Margaret V., Palmborg, Helena, Bystrická, Linda, Szamosi, Johan, Casiano, Sandra, Chambost, Hervé
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502440/
https://www.ncbi.nlm.nih.gov/pubmed/37720484
http://dx.doi.org/10.1016/j.rpth.2023.102163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502440/
https://www.ncbi.nlm.nih.gov/pubmed/37720484
http://dx.doi.org/10.1016/j.rpth.2023.102163

Ejemplares similares